Itraconazol Aurovitas

Itraconazole, the active ingredient in Itraconazol Aurovitas, is an azole antifungal presented as an oral dosage form for oral use. It treats a range of superficial and systemic fungal infections in adults and children as directed by a healthcare professional.

GNH USA supplies Itraconazol Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Clients benefit from reliable logistics and dedicated technical support throughout the procurement process.

Itraconazole is used to treat fungal infections affecting various organ systems and disease categories. - Aspergillosis: effective in managing invasive and chronic forms of Aspergillus infection. - Candidiasis: treats systemic and mucosal candidal infections, including esophageal and oropharyngeal disease. - Dermatophytosis: resolves superficial skin infections caused by dermatophyte fungi.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset or queasiness. - Headache: transient cranial discomfort. - Diarrhea: loose stools, often self‑limiting. - Abdominal pain: cramping or discomfort in the stomach area. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of congestive heart failure, especially in patients with pre‑existing heart disease. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photopsia. - Anaphylaxis: rare systemic allergic reaction requiring immediate medical attention.

Before initiating itraconazole therapy, consider the following precautions to ensure safe and effective use. - Liver function: assess baseline hepatic enzymes and monitor periodically during treatment. - Drug interactions: review concomitant medications for potential CYP3A4 interactions. - Cardiac status: avoid use in patients with known ventricular dysfunction or heart failure. - Pregnancy and lactation: evaluate risks and benefits; use only if clearly needed. - Renal impairment: adjust therapy in severe kidney disease as advised by a clinician. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Itraconazole interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce itraconazole exposure. - Certain statins (e.g., simvastatin, lovastatin): increased risk of rhabdomyolysis. - QT‑prolonging agents (e.g., quinidine, cisapride): may cause serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Proton pump inhibitors (omeprazole): can decrease itraconazole absorption. - HIV protease inhibitors (ritonavir): may increase itraconazole levels, necessitating dose adjustment.